269 related articles for article (PubMed ID: 19286302)
1. Insignificant prostate cancer and active surveillance: from definition to clinical implications.
Bastian PJ; Carter BH; Bjartell A; Seitz M; Stanislaus P; Montorsi F; Stief CG; Schröder F
Eur Urol; 2009 Jun; 55(6):1321-30. PubMed ID: 19286302
[TBL] [Abstract][Full Text] [Related]
2. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
Aus G
Eur Urol; 2009 Jun; 55(6):1331. PubMed ID: 19286303
[No Abstract] [Full Text] [Related]
3. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
Albertson PC
Eur Urol; 2009 Jun; 55(6):1331-2. PubMed ID: 19286304
[No Abstract] [Full Text] [Related]
4. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
Barocas DA; Cowan JE; Smith JA; Carroll PR;
J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
[TBL] [Abstract][Full Text] [Related]
5. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
6. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease.
Klotz LH
Can J Urol; 2005 Feb; 12 Suppl 1():53-7; discussion 101-2. PubMed ID: 15780167
[TBL] [Abstract][Full Text] [Related]
7. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.
Berglund RK; Masterson TA; Vora KC; Eggener SE; Eastham JA; Guillonneau BD
J Urol; 2008 Nov; 180(5):1964-7; discussion 1967-8. PubMed ID: 18801515
[TBL] [Abstract][Full Text] [Related]
8. Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era.
Ercole B; Marietti SR; Fine J; Albertsen PC
J Urol; 2008 Oct; 180(4):1336-9; discussion 1340-1. PubMed ID: 18707696
[TBL] [Abstract][Full Text] [Related]
9. Active surveillance for prostate cancer: has the time finally come?
Aragon-Ching JB
J Clin Oncol; 2010 Jun; 28(16):e265-6; author reply e267. PubMed ID: 20406916
[No Abstract] [Full Text] [Related]
10. Active Surveillance as Initial Management of Newly Diagnosed Prostate Cancer: Data from the PURC.
Botejue M; Abbott D; Danella J; Fonshell C; Ginzburg S; Guzzo TJ; Lanchoney T; Marlowe B; Raman JD; Smaldone M; Tomaszewski JJ; Trabulsi EJ; Uzzo RG; Reese AC
J Urol; 2019 May; 201(5):929-936. PubMed ID: 30720692
[TBL] [Abstract][Full Text] [Related]
11. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
12. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer.
Simpkin AJ; Tilling K; Martin RM; Lane JA; Hamdy FC; Holmberg L; Neal DE; Metcalfe C; Donovan JL
Eur Urol; 2015 Jun; 67(6):993-1005. PubMed ID: 25616709
[TBL] [Abstract][Full Text] [Related]
14. Active surveillance for favorable-risk prostate cancer: what are the results and how safe is it?
Klotz L
Curr Urol Rep; 2007 Sep; 8(5):341-4. PubMed ID: 17880830
[No Abstract] [Full Text] [Related]
15. Role of histopathology and molecular markers in the active surveillance of prostate cancer.
Montironi R; Egevad L; Bjartell A; Berney DM
Acta Oncol; 2011 Jun; 50 Suppl 1():56-60. PubMed ID: 21604942
[TBL] [Abstract][Full Text] [Related]
16. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
17. Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy?--A case control study.
Khatami A; Damber JE; Lodding P; Pihl CG; Hugosson J
Scand J Urol Nephrol; 2003; 37(3):213-7. PubMed ID: 12775279
[TBL] [Abstract][Full Text] [Related]
18. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience.
Carter HB; Kettermann A; Warlick C; Metter EJ; Landis P; Walsh PC; Epstein JI
J Urol; 2007 Dec; 178(6):2359-64; discussion 2364-5. PubMed ID: 17936806
[TBL] [Abstract][Full Text] [Related]
19. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
20. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review.
van den Bergh RC; Ahmed HU; Bangma CH; Cooperberg MR; Villers A; Parker CC
Eur Urol; 2014 Jun; 65(6):1023-31. PubMed ID: 24491309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
